Navigation Links
New molecular insight into amboebic dysentery
Date:6/14/2008

In the June 15th issue of G&D, Dr. Sinisa Urban (Johns Hopkins University School of Medicine) and colleagues reveal a potential role for the rhomboid enzyme, EhROM1, in the pathogenesis of the enteric protozoan parasite, E. histolytica. This discovery posits EhROM1 as a prospective target in the treatment of amoebic dysentery, which affects 1/10th of the global population (~500 million people) and represents the second most common disease in the world.

"New drug targets are needed for amebiasis as current treatments have associated toxicities and drug resistance is a concern." said Dr. Upinder Singh, a clinician at Stanford University and co-author of the study.

E. histolytica is a single-celled intestinal parasite that infects the lower GI tract, causing amoebiasis, and can invade the intestinal wall and spread to the bloodstream, causing potentially fatal amoebic liver abscesses. The parasite is transmitted through fecally contaminated food or water, and is a major public health threat in the developing world.

Dr. Urban and colleagues uncovered new insight into the activity of E. histolytica's single rhomboid protease protein, EhROM1, which suggests that it helps the parasite evade the host's immune response. In order to escape immune detection, E. histolytica trophozoites concentrate immune system-eliciting surface proteins towards the rear of the cell and then expel them. Dr. Urban's team discovered that EhROM1 processes surface lectin proteins, and collaborators at Stanford University found that it re-localizes posteriorly during lectin shedding.

These findings suggest that EhROM1 facilitates lectin shedding and host immune system evasion by this pathogenic parasite. Dr. Urban is excited by the new findings, since "Enzymes have served as particularly successful drug targets in the past, so it's exciting to discover an ameba rhomboid enzyme with similar properties as a malaria rhomboid. We're hopeful that with additional work, we will be able to develop rhomboid inhibitors and evaluate if they could be applied as a more general anti-parasitic strategy in the future."


'/>"/>

Contact: Heather Cosel-Pieper
coselpie@cshl.edu
Cold Spring Harbor Laboratory
Source:Eurekalert

Related medicine news :

1. Molecular insight begins Trofex Phase 1 trial for detection of metastatic prostate cancer
2. Molecular insight begins Trofex Ph. 1 trial for detection of metastatic prostate cancer
3. Siemens Showcases Innovative Leadership in Molecular Imaging at SNM 2008
4. Xceed Molecular Licenses Signature from Moffitt Cancer Center and Adds Moffitt to Strategic Collaborator Program
5. DiagnoCures molecular diagnostic tests - PCA3 and GCC - discussed at scientific meetings
6. Research reveals molecular fingerprint of cocaine addiction
7. SNM hosts 55th Annual Meeting of Nuclear Medicine and Molecular Imaging Research
8. Study identifies molecular response of cartilage to injury
9. Molecular change may reveal risk of leukemia relapse
10. Study Details New Molecular Approach to Preventing Alzheimers
11. Xceed Molecular Signs University of Florida to Strategic Collaborator Program; Focus on Developing New Molecular Test to Diagnose Early-Stage Bladder Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... ... January 23, 2017 , ... The TouchPoint Solution, ... who entered metrics into the product’s app. The data replicates and validates ... that within just 30 seconds of using Buzzies, people experienced a 74 percent ...
(Date:1/24/2017)... Michigan (PRWEB) , ... January 24, 2017 , ... The ... other advocates for drug and alcohol awareness, have worked with communities to designate the ... year, observed January 23-29, 2017, the theme is “Shatter the Myths.” As a ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... localization services for life science companies, has achieved ISO 17100:2015 certification following ... America. ISO 17100 is the globally recognized standard that establishes guidance for ...
(Date:1/23/2017)... ... 23, 2017 , ... The iaedp Foundation, recognized for its ... who treat the full spectrum of eating disorder problems, proudly announces the addition ... of the leading eating disorder treatments centers located throughout the U.S. As partners ...
(Date:1/23/2017)... ... 2017 , ... Sharon Kleyne, America’s leading water researcher, advocate and feared enemy ... of making new water infrastructure a number one priority. “As we usher in a ... infrastructure to become a top priority of our new political change agents.” Kleyne pointed ...
Breaking Medicine News(10 mins):
(Date:1/24/2017)... 23, 2017 ArisGlobal, a leading ... announces agClinical 3.3, the latest version of its comprehensive ... science organizations to confidently and efficiently meet new compliance ... the electronic trial master file so that compliance is ... ...
(Date:1/23/2017)... 2017  HOPE BIOSCIENCES announced today that it ... commercialize nuc -gemcitabine™ (APTA-12/HOPE-888) through a licensing ... nuc -Gemcitabine consists of Antisoma,s ... found on many cancer cells, and dFdCMP, an ... conjugates) or SMDCs (small molecule drug conjugates), which ...
(Date:1/23/2017)... 23, 2017  Therabron Therapeutics, Inc., a clinical-stage ... in respiratory care, today announced that the European ... has granted Orphan Drug Designation for Therabron,s CG367 ... Syndrome (BOS).  "We are pleased to ... to treat patients diagnosed with BOS following lung ...
Breaking Medicine Technology: